Life insurance after breast cancer

What the pathology report decides

Breast cancer underwriting runs almost entirely off the pathology report, and the items on it are weighted quite differently from one another.

Lymph node involvement is usually the most influential single finding. Disease confined to the breast with clear nodes is assessed on a different footing from disease that had reached the nodes, and where nodes were involved, how many matters. This one item moves outcomes more than any other in most breast cancer files.

Tumour size and stage follow. Small, early-stage disease is the most favourably assessed.

Grade describes how abnormal the cells appeared. A low-grade tumour is read more favourably than a high-grade one at the same stage.

Receptor status. Whether the tumour was hormone receptor positive or negative, and whether it was HER2 positive. These affect what treatment was appropriate and how the disease is expected to behave, and underwriters read them alongside stage rather than in isolation.

If you do not have this information, your oncologist’s records will. Knowing roughly where you sit before applying saves a great deal of back and forth.

DCIS is a different conversation

Ductal carcinoma in situ describes abnormal cells confined within the milk ducts that have not spread into surrounding breast tissue. It is non-invasive.

Insurers treat it substantially more favourably than invasive breast cancer. Waiting periods are typically much shorter, sometimes minimal, and standard rates are a realistic outcome for many applicants once treatment is complete.

If your diagnosis was DCIS, say so specifically rather than describing it as breast cancer generally. The distinction is real and it materially changes the assessment.

The endocrine therapy problem

This is the factor most people do not anticipate, and it is the most common reason a breast cancer application is postponed when the applicant expected it to be assessed.

Hormone receptor positive breast cancer is frequently followed by endocrine therapy, taken for several years after surgery, radiation and chemotherapy have all finished. Clinically this is preventive treatment aimed at reducing recurrence risk, and people reasonably think of themselves as finished with treatment once the acute phase is over.

Several insurers do not see it that way. Where the applicant is still taking endocrine therapy, some treat that as ongoing treatment, and the waiting period starts when it ends rather than when chemotherapy or radiation ended.

Insurers differ on this, and the difference is large. Some assess during endocrine therapy; others wait. It is one of the clearest cases in the whole health-conditions section where applying to a single insurer gives you a misleading picture of the market.

If you are on endocrine therapy, ask specifically how a given insurer treats it before applying.

Time, and how ratings behave

The waiting period after treatment varies with stage. Early-stage disease with clear nodes typically requires less time than node-positive disease, and advanced disease requires more.

What is worth knowing about breast cancer specifically is that ratings are often structured as temporary loadings that step down as years pass. Recurrence risk is highest in the earlier years after treatment and falls with time, and pricing often reflects that.

So an offer that looks expensive at three years out may be considerably better at seven, and the reduction may be built into the contract already. Ask whether the rating is time-limited and when it falls away, and get the answer in writing. Where it is not, a reconsideration on the strength of continued clean follow-up is often possible. See ratings and substandard offers.

Family history and genetic factors

Underwriters ask about breast and ovarian cancer in close relatives, particularly where diagnosis came at a young age, because a strong family pattern affects the assessment of future risk.

Genetic testing is treated differently in Canada. Under federal law, an insurer cannot require you to undergo a genetic test or to disclose the results of one as a condition of providing insurance. Your own diagnosis, treatment and medical history remain part of the application. The distinction is explained in how family medical history is used.

Reconstruction and surgery

Whether you had a lumpectomy, a mastectomy, or bilateral surgery is recorded, and it is read as information about the extent of disease rather than as a factor in its own right. Reconstruction itself is not a negative.

Preventive surgery undertaken because of a strong family history, in the absence of a cancer diagnosis, is a different situation and is assessed on its own terms.

Applying

Have the pathology details: stage, tumour size, node status, grade, receptor status, the treatments given with their dates, and whether endocrine therapy is ongoing and when it is due to end. Have your oncologist’s name and your most recent follow-up date.

Apply fully underwritten first, and apply through someone who can approach several insurers, because the variation on this condition is wide.

If treatment is still under way, the position is different and is covered in applying during active treatment.

The boundary

Nothing here is clinical information about breast cancer or its treatment. This page describes how an insurance file is read. Everything about your diagnosis, your treatment and your follow-up belongs with your oncology team.